Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Eribulin
Sponsor: SOLTI Breast Cancer Research Group
Collaborators: Eisai Inc.